Incyte Corporation: Carcinoma, Hepatocellular trials
The registry lists 13 Carcinoma, Hepatocellular studies with Incyte Corporation as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 11Phase 2 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of INCB086550 in Select Solid TumorsTerminatedNCT04629339Phase 2Results posted
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedNCT03277352Phase 1/2Results posted
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03241173Phase 1/2Results posted
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
- Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/2Results posted
- Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
- A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
- Study of INCA 0186 in Subjects With Advanced Solid TumorsTerminatedNCT04989387Phase 1
- INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 1